This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Partnering, Business Development & Licensing
search
Investment

BioNTech's Sean Marett explains Genentech deal rationale

Posted by on 14 July 2017
Share this article

Chief operating officer of BioNTech, Sean Marett, talks to Mike Ward, global director of content for Informa Pharma Intelligence, about the German firm's recent co-development deal with Roche company, Genentech. On the sidelines of the recent BIO-Europe® partnering conference, held in Cologne Germany, Marett outlines the benefits of this collaboration, such as access to the US market and regulatory expertise. This deal will be highlighted as part of a deal case study session at The One Nucleus Genesis meeting in London on December 1, 2016.


Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Sean Marett – COO, BioNTech

Share this article

Sign up for Partnering, Business Development & Licensing email updates

keyboard_arrow_down